Monoinstitutional real world experience in management of Vinflunine as second line therapy for transitional cell carcinoma of the urothelium

Vinflunine is the only cytotoxic agent tested as a second line therapy in transitional cell carcinoma of the urothelium in a phase III trial. It is not largely employed in clinical practice because of the high incidence of grade 3–4 toxicity. We evaluated efficacy and safety of Vinflunine at the dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Schinzari, Giovanni, Rossi, Ernesto, Pierconti, Francesco, Garufi, Giovanna, Monterisi, Santa, Strippoli, Antonia, D’Argento, Ettore, Cassano, Alessandra, Barone, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823567/
https://www.ncbi.nlm.nih.gov/pubmed/29492236
http://dx.doi.org/10.18632/oncotarget.24162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823567/
https://www.ncbi.nlm.nih.gov/pubmed/29492236
http://dx.doi.org/10.18632/oncotarget.24162

Ejemplares similares